Abnormal expression of major histocompatibility complex (MHC) molecules in melanoma has been reported previously. However, the MHC molecule expression patterns in different growth phases of melanoma and the underlying mechanisms are not well understood. Here, we demonstrate that in vertical growth phase (VGP) melanomas, MHC genes are subject to increased rates of DNA copy number gains, accompanied by increased expression, in comparison to normal melanocytes. In contrast, MHC expression in metastatic melanomas drastically decreased compared to VGP melanomas, despite still prevalent DNA copy number gains. Subsequent investigations found that the master transactivator of MHC genes, CIITA, was also significantly downregulated in metastatic melanomas when compared to VGP melanomas. This could be one of the mechanisms accounting for the discrepancy between DNA copy number and expression level in metastatic melanomas, a potentially separate mechanism of gene regulation. These results infer a dynamic role of MHC function in melanoma progression. We propose potential mechanisms for the overexpression of MHC molecules in earlier stages of melanoma as well as for its downregulation in metastatic melanomas.
INTRODUCTION
Melanoma, a malignant tumor that originates in melanocytes, is found predominantly in the skin. The stages of melanocytic progression are well documented. Dysplastic nevi first transform into melanoma in situ. Subsequently melanoma cells progress from the radial growth phase (RGP) to the vertical growth phase (VGP), and finally to the metastatic phase. Early detection is key in melanoma treatment. In the RGP phase, melanoma can be cured by surgical excision. However, if the progression of melanoma enters the VGP phase, it negatively impacts patient prognosis (Byers and Bhawan, 1998) .
The genes in MHC also called human leukocyte antigen (HLA), are clustered in a large genomic region on Chromosome 6. This group of genes encodes heterodimeric antigen-presenting proteins, crucial for the proper functioning of the immune system. There are three major MHC Class I genes, HLA-A, HLA-B, and HLA-C, and three major MHC Class II genes, HLA-DR, HLA-DQ, and HLA-DP. MHC Class I molecules present peptides derived from cytosolic proteins and interact exclusively with CD8 þ T cells, whereas
Class II molecules present peptides derived from extracellular proteins and interacts exclusively with CD4 þ T cells. MHC Class I molecules are displayed at the surface of most cells. MHC Class II molecules are constitutively expressed only in antigen-presenting cells, but can be induced to be expressed in other cell types in response to various stimuli of which IFN-c is the most potent and well known. Expression of MHC genes is mediated by multiple transcription regulators, for example the Class II transactivator (CIITA) is an essential regulator for the expression of Class II genes (Drozina et al., 2005) .
Additional Supporting Information may be found in the online version of this article.
Abnormities in MHC molecules have been studied extensively in cancer. The fact that downregulation of the MHC Class I molecules is frequently found in human cancer, including melanoma, and is often correlated with poor prognosis (Ogino et al., 2003 (Ogino et al., , 2006 Meissner et al., 2005) , suggests that it may contribute to escape of tumor cells from T-cell surveillance (Garrido et al., 1997; Koopman et al., 2000; Marincola et al., 2000; Ogino et al., 2003 Ogino et al., , 2006 Meissner et al., 2005; Norell et al., 2006; Chang and Ferrone, 2007) . In contrast, solid tumors of different histotypes were reported to express Class II molecules [reviewed in Altomonte et al. (2003) ] and selected tumor-associated antigens (TAAs) were effectively presented by MHC Class II molecules to CD4 þ T cells (Renkvist et al., 2001; Tatsumi et al., 2003) . However, the functions of the MHC Class II expression, as well as their clinical implications, are often controversial. For melanoma, earlier studies suggested that high expression of Class II antigens were associated with shorter survival (van Duinen et al., 1988) . In later studies, significant association of HLA Class II antigen expression with longer survival was reported in melanoma patients (Anichini et al., 2006) . Similar associations were also reported in large B-cell lymphoma and colorectal cancers (Rimsza et al., 2004; Matsushita et al., 2006) .
HLA Class I and Class II protein expression was studied in the human melanoma cell line collection from the European Searchable Tumor Cell Line Database (ESTDAB; Rodriguez et al., 2007; Mendez et al., 2008 Mendez et al., , 2009 . In 67% of the cell lines, HLA Class I expression was downregulated via various mechanisms. HLA Class II expression was found in a subset of the 42 cell lines studied, and there seemed to be positive correlation between Class I and Class II expression. Since immunological events seem to be intimately involved in the clinical course of this disease (Mortarini et al., 2003) , and no systematic study has been done to compare MHC class molecule expression in different stages of melanoma development, we used DNA and expression microarray data from an extended collection of melanoma cell lines established from patients to identify distinct patterns of expression of MHC and MHC-related genes in VGP and metastatic melanoma cells. Based on these results, we propose potential mechanisms for the overexpression of MHC molecules in VGP and downregulation of these molecules in metastatic melanoma relative to VGP.
MATERIALS AND METHODS

Cell Lines and Cell Culture
Normal melanocytes and primary melanoma cell lines were obtained from M. Herlyn (Wistar Institute, Philadelphia, PA). Human melanocytes and melanoma cells were maintained in media as described previously (Satyamoorthy et al., 2003) and were grown at 37 C and 10% CO 2 .
Microarray Analysis for Gene Expression and Copy Number Changes
Microarray-based gene expression analysis was done using the Affymetrix HG-U133A chips (Affymetrix, Sunnyvale, CA). Labeling and hybridization steps were carried out as described previously (Tsavachidou et al., 2004) . All gene expression analyses were done using the R statistical programming language and several accompanying Bioconductor packages (Gentleman et al., 2004) . First, raw cell files were subject to quantile normalization. Probes not expressed to a mas5 normalized intensity value of at least 100 in more than 25% of all samples were removed from the data set. To determine which genes appear differentially expressed between VGP and metastatic groups, every probe set was subject to a groupwise comparison with a t test where the significance level was adjusted for multiple comparisons. All genes with a P value <0.05 were considered to be differentially expressed between groups. Microarray DNA copy number profiling was done for 52 melanoma cell lines. All cell lines were assayed on a microarray composed of 4,134 bacterial artificial chromosomes (BACs) and hybridization protocols described in detail by Naylor et al. (2005) . Samplewise data normalization was done under the assumption that the mean copy number of each melanoma was diploid. Subsequent data visualization and analysis was performed using the CGHAnalyzer software suite (Margolin et al., 2005) . All primary and processed profiling data were deposited in NCBI's Gene Expression Omnibus repository for public access (Tsavachidou et al., 2004; Hoek et al., 2006; Greshock et al., 2009 ).
Ingenuity Analysis
The Ingenuity Pathway Analysis software (IPA, Ingenuity Systems, Mountain View, CA) was used to map genes into different pathways and for visualization. For copy number studies, gene amplification and deletion frequencies were input into Ingenuity. Significant ''nodes'' were noted where alteration frequencies exceeded 20% (colored red and green in the case of DNA gains and losses, respectively). For expression studies, Ingenuity input was limited to differentially expressed genes having fold changes of >1.5 between tumor stage groups. The significantly overexpressed genes are colored green and the significantly underexpressed genes are colored red.
Transcript Validation by Taqman Gene Expression Assays
HLA-DRA, CD74, and CIITA transcript levels relative to b-actin were measured in each melanoma cell line by one step real-time qPCR analysis using Applied Biosystems Prism (ABI) 7900HT Sequence Detection System as described previously (Mu et al., 2003) . Taqman primers and probes for b-actin and HLA-DRA were designed using Primer Express software (Applied Biosystems, Foster City, CA). The sequences for each gene are: HLA-DRA-QF, GGGTCTGGTGGGCATCATTA; HLA-DRA-QR, TTCTGCTGCATTGCTTTTGC; HLA-DRA-QP, CAATCCCTTGATGATGAAGATGG TCCCA; H-ACTIN-QF, GCAAAGACCTGTAC GCCAACA; H-ACTIN-QR, TGCATCCTGTCG GCAATG; and H-ACTIN-QP, TGGCGGCAC CACCATGTACCC. The CD74 and CIITA primers and probes were purchased from ABI gene expression assays collection. The assay ID for CD74 is Hs00269961_ml, and the assay ID for MHC2TA is Hs00172094_ml.
Western Blot Analysis
Protein levels were measured in all cell lines for CD74 and HLA by Western blot analysis. First, cells were lysed in M-PER Mammalian Protein Extraction Reagent (PIERCE, Rockford, IL) following manufacturer's protocol. Following SDS-PAGE and transfer onto a PVDF membrane (Millipore, Billerica, MA), the membrane was blocked in 5% milk in Tris-buffered saline containing 0.1% (v/v) Tween 20 (TBCT) and subsequently probed with anti-CD74 (GeneTex, San Antonio, TX) at 1:50 dilution or anti-HLA (Abcam, Cambridge, MA) at 1:300 dilution. The catalog number for the Abcam antibody is ab8085 and recognizes HLA DR þ HLA DP. GAPDH control antibody was purchased from Abcam and was used at 1:1,000 dilution.
RESULTS
Frequent Copy Number Gains at Chromosome Arm 6p in Melanoma Cell Lines
The copy number status of all MHC loci was derived by CGH assay using the clone directly covering the respective region, or by identifying the nearest mapping clone. This was done using the ''flanking regions'' function implemented by the CGHAnalyzer software. Copy number gains were defined where clone's log 2 copy number exceeded 0.25, while losses were defined when the clone's log 2 copy number was less than À0.25. A total of 95 melanomas [52 cell lines ( Fig. 1A and Supporting Information Table S1 ) and 43 tumor tissues ( Fig. 1B and Supporting Information Table S2 )] were analyzed for DNA copy number changes (Greshock et al., 2009) . Copy number gains of MHC-I and MHC-II (6p21.32) are common in melanomas, where 32.7% (17/52) of cancer cell lines and 25.6% (11/ 43) of tumor tissues harbor a copy number gain. In all but three cases (one cell line and two tumor tissues), the copy number gains were less than $5 copies (log 2 ratio 0.25-0.65). There were no significant differences in copy number gain frequency when stratifying by the presence of BRAF or NRAS mutations (Fig. 1 ).
Correlation of MHC Gene Amplification and Overexpression in VGP Melanoma Cell Lines
To assess concurrent aberrations at both DNA and RNA levels for different canonical pathways in melanomas, with the specific emphasis on the antigen-presenting pathway, we analyzed genome-wide microarray-based gene expression profiling data for a subset of cell lines described above, including 5 melanocytes, 13 VGP cell lines, and 18 metastatic cell lines (Supporting Information Table S3 ; Tsavachidou et al., 2004; Hoek et al., 2006) . Significantly differentially expressed genes were crosstabulated for each pair of diagnosis groups. This includes comparisons of VGP melanoma lines and melanocytes, metastatic melanoma and melanocytes, and metastatic and VGP. The deletion and amplification frequencies calculated by aCGH data were aligned with differentially expressed gene lists from expression microarray data and imported into the Ingenuity pathways analysis software. For VGPs, MHC genes located on 6p21-22 showed frequent copy number gains. In addition to MHC-IIa, MHC IIb, and MHC-I-a genes, these also include LMP2, LMP7, TAP1, TAP2, and TPN (Supporting Information Fig. 1 ). In contrast, MHC-Ib molecules like B2M, which maps to 15q21, were not gained (and even deletion was observed in some cell lines). Also CLIP (CD74 antigen, MHC II-c chain), which is located on 5q32, did not show frequent copy number gains. The same genes that showed copy number gains on Chromosome 6, including MHC-IIa genes, MHC-IIb genes, MHC-Ia genes, LMP2, LMP7, and TAP2, were all overexpressed in VGP cell lines when compared to normal melanocytes as well ( Fig. 2A and Table 1 ). In contrast, MHC-Ib genes, which are not located on Chromosome 6, did not show copy number gains and were also not upregulated in VGP. The exceptions are TAP1, which was not overexpressed despite frequent copy number gains in VGP, and CLIP, which is on 5q32 and did not show DNA copy number alterations, but was significantly upregulated in VGP. Overall, however, there is a good correlation between the copy number gains on Chromosome 6 and the enhanced expression of the MHC gene cluster for VGP melanoma cell lines. 
Expression of MHC Genes is Downregulated in Metastatic Melanoma Cell Lines Compared to VGP Lines
In contrast to VGP cell lines, metastatic melanoma cell lines generally showed a lack of correlation between DNA amplification and gene expression. While in metastatic cell lines copy number gains were frequently detected in MHCIIa, MHC-IIb, MHC-Ia, TAP, and LMP (all located on Chromosome 6) (Supporting Information Fig. 2 ), multiple MHC-Ia genes were in fact significantly downregulated ( Fig. 2B and Table 2 ). Other genes showed similar expression between metastatic melanoma lines and melanocytes. HLA-DRB1 and CD74 were the only two genes still overexpressed, but the enhancement in expression ($2 folds) was far less compared to the enhancement in VGP lines ($14 fold). Thus, all components of the antigen-presenting pathway were significantly downregulated in metastatic lines when compared to VGP. This relationship can be observed in the Ingenuity software ( Fig. 3 and Table 3 ). These not only include the MHC genes on Chromosome 6, but also the MHC-Ib gene B2M on Chromosome15 and CD74 on Chromosome 5. In fact, unbiased Ingenuity analysis of the significantly altered pathways between metastatic and VGP cell lines identified the most significant pathway as the antigen presentation pathway (P ¼ 9.54 Â 10 À14 ). To validate the expression changes observed with microarray, PCR-based gene expression assays were performed on two MHC molecules, CD74 (HLA-DG) and HLA-DRA. Both CD74 and HLA-DRA were not detectable in melanocytes, but were expressed at high levels in VGP cell lines (Fig. 4) . Notably, in VGP lines, when comparing to DNA amplification, for all of the cell lines that showed HLA-DRA gene amplification, overexpression was also observed (Table 4) . However, for certain VGP cell lines with no DNA amplification, overexpression was also observed, suggesting DNA amplification could be one of the mechanisms contributing to the overexpression of the MHC molecules in VGP lines. In metastatic cell lines, the expression of CD74 and HLA-DRA was significantly reduced comparing to VGP lines (Fig. 4) . Some metastatic cell lines did show certain degree of low level expression, while none of the melanocytes had any detectable level of CD74 or HLA-DRA mRNA expression by Taqman. This was further confirmed with Western blot analysis for protein level detection of the same two molecules in a subset of the cell lines with RNA data (Fig. 4, top portion) . The control GAPDH level was relatively constant among the cell lines. Together, these results revealed a shift of expression pattern of the HLA genes as melanoma cells progress from the VGP to the stage of metastasis.
Downregulation of CIITA in Metastatic Melanoma Cell Lines
CIITA is an important transactivator of MHC-II genes. To investigate the possible mechanism of decreased MHC-II expression in metastatic melanoma cell lines, we assessed the mRNA expression of CIITA by using RT-Taqman. CIITA was not expressed in melanocytes, but it was highly expressed in VGP cell lines. In contrast, the majority of metastatic cell lines showed undetectable or low level of CIITA expression (Fig. 5) . This downregulation of CIITA from VGP to metastasis may be responsible for the reduced expression of MHC-II in the metastatic cell lines.
DISCUSSION
Although MHC molecule abnormalities are frequently found in melanoma cells, their stage-specific expression has not been well documented.
The results presented here demonstrate that the expression of MHC molecules in melanomas varies greatly by tumor stage. When analyzed separately, VGP and metastatic melanoma demonstrate unique patterns of MHC expression despite similar trends in DNA copy number. Specifically, multiple MHC-I and MHC-II genes were overexpressed in VGP melanoma but not in metastatic melanomas.
MHC-I expression was reported to be downregulated in melanoma (Ferrone and Marincola, 1995) as well as in melanoma cell lines (Mendez et al., 2008) . Here, we discovered that this downregulation is tumor stage specific. Multiple MHC-I molecules were significantly downregulated in metastatic melanoma cell lines relative to melanocytes (Table 2) , consistent with previous reports. However, for the VGP lines, the downregulation was rare (Table 1) . In fact, multiple MHC-I molecules were expressed at significantly higher level in VGP lines than in melanocytes. Comparison of metastatic cell lines with VGP lines showed overall lower expression of MHC-I molecules in metastatic cell lines (Table 3) . A cautionary note is that this is a genomic study that examined changes at the mRNA level, while most of the earlier studies were using antibodies to detect protein expression on cell membrane. It is possible that MHC-I complexes could be further downregulated via other mechanisms mentioned previously (Mendez et al., 2008) . By using a microarray platform, we were able to look at the overall picture of all of the MHC molecules, while protein studies are restricted to one molecule at a time and are limited by antibody availability and specificity, among other characteristics. At least at mRNA level, there seem to be significantly less MHC-I expression in metastatic cell lines comparing to VGP lines. HLA Class I alteration was reported in 67% of the ESTDAB melanoma cell lines (Mendez et al., 2008) . It would be interesting to find out if the cell lines that did not show alteration are enriched with VGP lines.
Constitutive expression of MHC-II molecules is usually restricted to the cells of the immune system and thymic epithelial cells (Mach et al., 1996) . However, different tumors have been reported to express MHC-II molecules (Altomonte et al., 2003) . Here, we identified that the VGP melanomas were the predominant type overexpressing the MHC-II molecules. There was a significant downregulation of the MHC-II expression in metastatic cell lines relative to the VGP lines (Table 3 ). In the ESTDAB collection of melanoma cell lines, it was also noted that MHC-II expression was only observed in a portion of the cell lines, while 24 out of 42 cell lines had no constitutive or IFN-c-induced expression. In a different study on VGP and lymph node metastases, though consistent with our result that VGP tumors expressed MHC-II molecules, MHC-II expression was also reported in a subset of lymph node metastases and was found to correlate with better survival (Anichini et al., 2006) . It has been reported that melanomas isolated at different body sites, with different UV exposures, etc., can have distinct sets of genetic alterations and consequently different expression profiles (Curtin et al., 2005) . Additionally, the expression of HLA molecules is greatly influenced by IFNc. All of the metastatic cells in the article by Anichini et al. (2006) were isolated from lymph nodes and were only grown in short culture, which might play a role in more MHC Class II molecule expression as well. We did notice that in some metastatic cell lines, like WM1361B, there was expression of HLA-DRA, but at a low level (Table 4 and Fig. 4) . It would not be very surprising if the expression levels were increased dramatically upon IFN-c treatment.
The shift in gene expression pattern in metastatic melanomas from that seen in VGP, with significantly reduced expression of multiple MHC Class I and II genes in metastatic melanomas, indicates a mechanism of tumor cell immune evasion and supports the cancer immune surveillance theory. The change of MHC expression during progression from VGP to metastasis also suggests different roles of MHC molecules in different stages of melanoma. MHC molecules may function in promoting tumor progression and local tumor-specific immune suppression in nonmetastasis stages, such as the VGP stage, possibly via mechanisms mentioned previously (Aoudjit et al., 2004; Wang et al., 2005) . Conversely, in metastatic melanoma cells, eliminating MHC-II expression in conjunction with downregulation of MHC-I may further enhance immune evasion of melanoma cells. This may facilitate the process of metastasis that includes invasion, intravasation, extravasation, and the growth of secondary tumor.
In this study, we also observed that the overexpression of the MHC molecules in VGP cells were associated with copy number gains at the MHC complex loci on chromosome arm 6p. The fact that multiple genes located in the same genomic loci on Chromosome 6 exhibited increase in mRNA level, and this increase was not observed for genes not on Chromosome 6 like the MHC-Ib molecules, suggests that DNA amplification contributed to the overexpression of the MHC molecules in VGP. We did notice that for all the VGP lines that had amplification in the MHC loci, HLA-DRA expression was upregulated. But for some VGP lines that did not show DNA amplification, overexpression was also observed (Table 4) . This is often seen in the cases of oncogene amplification and overexpression, in that overexpression exceeds amplification, suggesting that DNA amplification is just one of the mechanisms to upregulate the expression of a gene that is needed for cancer progression (Prins et al., 1993; Hynes and MacDonald, 2009; Kim and Salgia, 2009) . Despite the frequent occurrence of DNA copy number gains also in metastatic cells, MHC molecule expression level was significantly lower than VGP. While copy number gains in VGP and metastatic melanomas at the MHC loci could contribute to the overexpression of the MHC genes, metastatic melanomas may harbor additional mechanisms involved in regulating the expression of MHC molecules that ''override'' the effect of copy number gain and lead to decrease of gene expression.
Interestingly, studies on different mechanisms that could lead to loss of MHC-I expression in the ESTDAB melanoma cell line collection revealed LOH of the MHC loci on chromosome arm 6p as one of the potential mechanisms (Rodriguez et al., 2005; Mendez et al., 2008) . 6p21, the region discussed in this article, is one of the regions frequently found to be amplified in human cancers including melanoma (Santos et al., 2007) . It appeared not to be a cell line artefact, since we observed this amplification in both cell lines as well as melanoma tumors. 6p amplification was also reported in other studies on primary and metastatic melanomas (Balazs et al., 2001 ). The most compelling evidence came from Table 4 in the same order. The protein extracts were made from a subset of these cell lines and probed for HLA-DRA and CD74 protein levels by Western. GAPDH was used as loading control. a report on 126 melanomas, where 6p amplification was reported to be a frequent event in melanoma (Curtin et al., 2005) . There could be multiple reasons for the discrepancy. One possibility is different tissue collection; melanomas isolated at different body sites, with different UV exposure, etc., can have distinct sets of genetic alterations (Curtin et al., 2005) . Another possibility is different methods; most of the 6p LOH reports were done using microsatellite marker amplification, while 6p amplification was detected using CGH method to reflect dosage change. As reported in this article, most of the 6p copy number gains are low level gains of less than five copies. It is possible that one allele can be lost and the other allele is amplified and the net result is still the gain of dosage. We did notice that for the ESTDAB collection, although 6p LOH was reported based on microsatellite marker analysis, the FISH result always showed at least two hybridization signals, and often three or four signals (Mendez et al., 2008) , consistent with our observation of low level DNA amplification at 6p. The fact that for most of the cell lines in the ESTDAB collection downregulation of HLA locus could be reversed after treatment with IFN-c makes it highly unlikely that loss occurred at a DNA level. Since reports indicated that the frequent constitutive expression of MHC-II molecules in melanoma cells was caused by abnormal constitutive transcription of CIITA (Deffrennes et al., 2001; Goodwin et al., 2001) , the master regulator of MHC-II gene expression, we explored the expression of CIITA as a potential mechanism of MHC-II downregulation in metastatic melanoma cells. We note the same pattern of CIITA expression as the expression of MHC-II molecules, using CD74 and HLA-DRA as examples. CIITA expression was high in VGP cell lines but decreased dramatically in metastatic cell lines (Fig. 5 ), suggesting that reduced CIITA level may be responsible for downregulation of MHC-II in metastatic melanoma cells relative to VGP lines. Thus, despite DNA copy number gains, MHC-II expression in metastatic melanoma is possibly controlled by the transcriptional activity of CIITA. Possible mechanisms of CIITA expression reduction include promoter methylation, deacetylation of histone, or methylation of Histone H3 lysine 9 (van den Elsen et al., 2004; Holling et al., 2006; Wright and Ting, 2006) . We also observed downregulation of MHC-I molecules in metastatic melanoma. The potential mechanisms for MHC-I underexpression can be epigenetic silencing or regulation by transcriptional factors (van den Elsen et al., 2003) . Interestingly, it was also shown that CIITA has a role in MHC-I expression (Martin et al., 1997) , suggesting potential contribution of CIITA to the downregulation of MHC-I in metastatic melanoma.
In conclusion, this study explored MHC class molecule expression in different stages of melanoma. We have revealed a distinct pattern of MHC expression with tumor stage despite similar DNA copy number changes. Further, we identified potential causes of this shift in gene expression pattern. Since immunological events play such important roles in the clinical course of melanoma, besides serving as molecular markers of melanoma progression, the distinct expression pattern of MHC molecules in metastatic melanoma versus VGP can also have important implications in immunological interventions against the disease. Figure 5 . Taqman gene expression assay shows that in concordance with HLA-DRA expression, CIITA is highly expressed in VGP cell lines, but is nondetectable in melanocytes and expressed at very low level in metastatic cell lines. HLA-DRA and CIITA mRNA levels were measured by rt-Taqman, and relative expressions to b-actin were plotted side-by-side for the same cell lines. The result presented here is the average of two independent data points from a single experiment. The same experiment was done twice with similar results. The names of the cell lines in the figure are listed in Table 4 in the same order.
